KA/EN
Register
Medicines reference
Search
Search
Active substance

Insulin human

Favourites

Insulin (human, recombinant). Registered in Georgia: 1 human medicine. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Insulin human
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.1 IU/kg
off-label
 Dog, Cat Diabetic Ketoacidosis Intramuscular every hour until blood glucose is below 250 mg/dL, then subcutaneously every 4–6 hours
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Diabetes Mellitus in Dogs and Cats
MSD/Merck Veterinary Manual, 2024
0.2 IU/kg
off-label
 Dog, Cat Diabetic Ketoacidosis
Loading
 Intramuscular once
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Diabetes Mellitus in Dogs and Cats
MSD/Merck Veterinary Manual, 2024
2.2 IU/kg
off-label
 Dog Diabetic Ketoacidosis
CRI (Continuous Infusion)
 Intravenous Continuous
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Diabetes Mellitus in Dogs and Cats
MSD/Merck Veterinary Manual, 2024
0.25–0.5 IU/kg
off-label
 Dog, Cat Hyperkalaemia
Emergency
 Intravenous once
MSD Vet Manual 2025
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Urethral Obstruction in Small Animals
MSD/Merck Veterinary Manual, 2025
0.25 IU/kg
off-label
 Dog, Cat Hyperkalaemia
Emergency
 Intravenous once
MSD Vet Manual 2025
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Obstructive Uropathy in Dogs and Cats
MSD/Merck Veterinary Manual, 2025
0.2 IU/kg
off-label
 Dog, Cat Hyperkalaemia
Emergency
 Intravenous once
MSD Vet Manual 2025
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Cardiopulmonary Resuscitation of Small Animals
MSD/Merck Veterinary Manual, 2025
1.1 IU/kg
off-label
 Cat Diabetic Ketoacidosis
CRI (Continuous Infusion)
 Intravenous Continuous
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Diabetes Mellitus in Dogs and Cats
MSD/Merck Veterinary Manual, 2024
Before use

Safety information

Known Contraindications

  • Critical
    Hypersensitivity to human insulin or any product component is a contraindication.
    Source: EMA Sources: EMA
  • Warning
    Hypoglycaemia (BG <3.0 mmol/l [54 mg/dl])... can be life-threatening and should be treated rapidly.
    Sources: ISFM · MSD Vet Manual
  • Caution
    When regular insulin is used for life-threatening hyperkalaemia in hypoadrenocorticism, check blood glucose every 30–60 minutes because the patient may already be hypoglycaemic and is predisposed to further hypoglycaemia. Give dextrose with or after insulin as required. Specific hyperkalaemia treatment is generally reserved for life-threatening bradyarrhythmia or failure of initial fluid resuscitation to improve potassium within 30–60 minutes.
    Sources: MSD Vet Manual

Known Drug Interactions

  • Major warning Dexamethasone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Prednisolone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Minor warning Levothyroxine + Insulin human
    Starting or changing levothyroxine supplementation in a diabetic dog receiving insulin can alter the insulin requirement.
    Recommendation: Monitor glycaemic control frequently when starting levothyroxine.
Latin name
Insulin human
Georgian name
ადამიანის ინსულინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 1 forms
Products
Actrapid
Human medicines in Georgia
Actrapid, Actrapid HM Penfill, Insulatard
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Actrapid 100 IU/ml, Solution

10 ml vial, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation
7.6/10
Good
vetman assessment

Actrapid

100 IU/ml, 10 ml vial, solution for injection, human medicine
Assessed clinical scopeDog · Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation · IV,IM
Care settingEmergency/critical-care hospital with frequent bedside glucose, electrolyte and ECG monitoring
vetman score 7.6/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-035270 · Verified on 15 Oct 2026 Off-label use

A strong, well-characterised hospital option for canine DKA and selected life-threatening hyperkalaemia. Exact-product transparency and direct regular-insulin evidence are major strengths; off-label status and the need for intensive glucose, potassium and phosphorus surveillance keep it below the very-good band.

Regulatory and scientific credibility8.5/10

The exact 100 IU/ml 10 ml Novo Nordisk vial has a transparent central EMA dossier and current Georgian and EU/GB human registrations. Soluble recombinant human insulin has direct veterinary protocol evidence, but Actrapid has no dog/cat authorisation and the assessed emergency indications remain off-label.

Clinical efficacy8.0/10

Prospective and randomized canine studies show that titrated IV regular insulin reliably lowers glucose and resolves ketosis in most dogs; direct evidence also defines electrolyte needs and shows that fixed-rate infusion is usable but not clearly superior. Insulin plus dextrose is an established temporary potassium-shifting intervention, while definitive treatment must correct the cause.

Safety and tolerability6.5/10

The dominant risks are predictable but potentially serious hypoglycaemia, hypokalaemia, hypophosphataemia and an excessively rapid glucose fall. With correct dilution, dextrose support and frequent reassessment they are usually manageable; dosing-equipment errors, delayed hypoglycaemia and use before restoring perfusion can cause major harm.

Clinical practicality7.0/10

The ready 100 IU/ml solution is rapidly titratable by IV infusion or protocolled IM dosing and needs no reconstitution. It does require U-100 equipment, accurate bag or syringe preparation, allowance for container adsorption, IV access and repeated glucose/electrolyte checks; these are appropriate ICU burdens. A 1,000-IU vial may be wasteful when emergency use is infrequent.

Full-course cost-effectiveness-

Current comparable local treatment-course and hospital-use prices were not verified.

Important safety and use flags

  • This score covers acute monitored hospital use for DKA and selected life-threatening hyperkalaemia only. It does not rate chronic maintenance diabetes, routine home SC administration, every mild potassium elevation or any unmonitored protocol.
  • The exact Actrapid vial is a human medicine and all assessed dog/cat uses are off-label. Record the product, U-100 concentration, route, protocol, infusion preparation and total delivered exposure; do not substitute another insulin formulation or concentration by name alone.
  • Use only U-100 insulin syringes or a validated infusion system. U-40 equipment, decimal-place errors, confusing IU with ml or copying the amount added to a bag as a direct bolus can cause a potentially fatal overdose.
  • Stabilise perfusion and start appropriate fluids before insulin in DKA unless the selected emergency protocol clearly requires otherwise. Confirm DKA with ketones and acid-base assessment, identify precipitating disease and do not treat hyperglycaemia alone as DKA.
  • For DKA, measure glucose at least every 1–2 hours during aggressive treatment and avoid a fall faster than the selected protocol target. Measure potassium and phosphorus repeatedly, supplement when indicated, follow ketones and acid-base status, and add dextrose while continuing insulin when glucose reaches the protocol threshold.
  • For hyperkalaemia, insulin shifts potassium temporarily and must be paired with dextrose unless a documented exceptional circumstance dictates otherwise. Recheck glucose and potassium for delayed hypoglycaemia or rebound, protect the myocardium with calcium when indicated, and remove potassium by treating the cause.
  • Hypoadrenocorticism may present with baseline hypoglycaemia and often improves with fluids and glucocorticoids. Reserve insulin for selected severe persistent hyperkalaemia, give dextrose and check glucose every 30–60 minutes; never let potassium shifting delay definitive crisis treatment.
  • Prepare IV dilution aseptically and account for adsorption to tubing or the infusion container. Prime according to the local validated protocol, label the final IU/ml prominently, use a dedicated line where feasible and independently double-check calculations, pump settings and patient weight.
  • Do not use a cloudy, coloured, frozen, overheated or otherwise damaged solution. Store unopened vials at 2–8 C, protect from light, do not freeze, and follow the exact label after opening; the human product information permits six weeks below 25 C in use.
  • Review concurrent glucocorticoids, progestogens, dextrose, beta-agonists, diuretics and other agents that alter glucose or potassium. Dose changes must follow bedside measurements rather than a fixed schedule; hypersensitivity to human insulin or an excipient is a contraindication.
Assessment sources
  1. Actrapid EMA EPAR2020
  2. Actrapid GE register2026
  3. Dog/cat DKA insulin RCT2024
  4. Canine regular-insulin DKA trial1993
  5. Feline regular-insulin doses2010
  6. Feline regular-insulin CRI2015
  7. Feline DKA protocol pilot2015
  8. Canine DKA insulin comparison2020
  9. Dog/cat hyperkalaemia review2026
  10. Canine Addison crisis management2010
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation
7.4/10
Good
vetman assessment

Actrapid

100 IU/ml, 10 ml vial, solution for injection, human medicine
Assessed clinical scopeCat · Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation · IV,IM
Care settingEmergency/critical-care hospital with frequent bedside glucose, electrolyte and ECG monitoring
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-035270 · Verified on 15 Oct 2026 Off-label use

A clinically useful hospital option for feline DKA and selected life-threatening hyperkalaemia. Exact-product transparency and direct feline regular-insulin evidence support a good score, while smaller heterogeneous studies and intensive biochemical monitoring keep confidence and efficacy below the canine assessment.

Regulatory and scientific credibility8.5/10

The exact 100 IU/ml 10 ml Novo Nordisk vial has a transparent central EMA dossier and current Georgian and EU/GB human registrations. Soluble recombinant human insulin has direct veterinary protocol evidence, but Actrapid has no dog/cat authorisation and the assessed emergency indications remain off-label.

Clinical efficacy7.5/10

Feline evidence directly supports IV CRI and intermittent IM regular-insulin protocols, but studies are small and heterogeneous, recent ketosis resolution was less consistent than in dogs, and no regimen is uniformly superior. Insulin plus dextrose is an established temporary potassium-shifting intervention, not definitive potassium removal.

Safety and tolerability6.5/10

The dominant risks are predictable but potentially serious hypoglycaemia, hypokalaemia, hypophosphataemia and an excessively rapid glucose fall. With correct dilution, dextrose support and frequent reassessment they are usually manageable; dosing-equipment errors, delayed hypoglycaemia and use before restoring perfusion can cause major harm.

Clinical practicality7.0/10

The ready 100 IU/ml solution is rapidly titratable by IV infusion or protocolled IM dosing and needs no reconstitution. It does require U-100 equipment, accurate bag or syringe preparation, allowance for container adsorption, IV access and repeated glucose/electrolyte checks; these are appropriate ICU burdens. A 1,000-IU vial may be wasteful when emergency use is infrequent.

Full-course cost-effectiveness-

Current comparable local treatment-course and hospital-use prices were not verified.

Important safety and use flags

  • This score covers acute monitored hospital use for DKA and selected life-threatening hyperkalaemia only. It does not rate chronic maintenance diabetes, routine home SC administration, every mild potassium elevation or any unmonitored protocol.
  • The exact Actrapid vial is a human medicine and all assessed dog/cat uses are off-label. Record the product, U-100 concentration, route, protocol, infusion preparation and total delivered exposure; do not substitute another insulin formulation or concentration by name alone.
  • Use only U-100 insulin syringes or a validated infusion system. U-40 equipment, decimal-place errors, confusing IU with ml or copying the amount added to a bag as a direct bolus can cause a potentially fatal overdose.
  • Stabilise perfusion and start appropriate fluids before insulin in DKA unless the selected emergency protocol clearly requires otherwise. Confirm DKA with ketones and acid-base assessment, identify precipitating disease and do not treat hyperglycaemia alone as DKA.
  • For DKA, measure glucose at least every 1–2 hours during aggressive treatment and avoid a fall faster than the selected protocol target. Measure potassium and phosphorus repeatedly, supplement when indicated, follow ketones and acid-base status, and add dextrose while continuing insulin when glucose reaches the protocol threshold.
  • For hyperkalaemia, insulin shifts potassium temporarily and must be paired with dextrose unless a documented exceptional circumstance dictates otherwise. Recheck glucose and potassium for delayed hypoglycaemia or rebound, protect the myocardium with calcium when indicated, and remove potassium by treating the cause.
  • Hypoadrenocorticism may present with baseline hypoglycaemia and often improves with fluids and glucocorticoids. Reserve insulin for selected severe persistent hyperkalaemia, give dextrose and check glucose every 30–60 minutes; never let potassium shifting delay definitive crisis treatment.
  • Prepare IV dilution aseptically and account for adsorption to tubing or the infusion container. Prime according to the local validated protocol, label the final IU/ml prominently, use a dedicated line where feasible and independently double-check calculations, pump settings and patient weight.
  • Do not use a cloudy, coloured, frozen, overheated or otherwise damaged solution. Store unopened vials at 2–8 C, protect from light, do not freeze, and follow the exact label after opening; the human product information permits six weeks below 25 C in use.
  • Review concurrent glucocorticoids, progestogens, dextrose, beta-agonists, diuretics and other agents that alter glucose or potassium. Dose changes must follow bedside measurements rather than a fixed schedule; hypersensitivity to human insulin or an excipient is a contraindication.
Assessment sources
  1. Actrapid EMA EPAR2020
  2. Actrapid GE register2026
  3. Dog/cat DKA insulin RCT2024
  4. Canine regular-insulin DKA trial1993
  5. Feline regular-insulin doses2010
  6. Feline regular-insulin CRI2015
  7. Feline DKA protocol pilot2015
  8. Canine DKA insulin comparison2020
  9. Dog/cat hyperkalaemia review2026
  10. Canine Addison crisis management2010
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Insulin human100 IU/ml
Formulation Type
Solution
Administration route
Subcutaneous, Intramuscular, Intravenous
Manufacturer
Novo Nordisk · Denmark
Registration
Georgia Yes, human
In force until 20 May 2027
Human (Ministry of Health, RAMA)
№ რ-035270
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PLGB046680354
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗